Public Research

  • |

    Xtandi’s Public-Science Tollbooth

    ByPhil McCracken

    The Xtandi money trail starts, in the account at issue, with publicly supported UCLA research, including support attributed to the NIH and the Department of Defense, and leads to a medicine associated with Astellas and Pfizer. The stated annual price is $180,000—not a claim that every patient pays that amount out of pocket. That is quite a trip for a public contribution: it leaves the lab as civic support and arrives at the pharmacy wearing a velvet-rope wristband.

    I follow the invoice, not just the discovery. Public research deserves support, but public support should count for more than a polite thank-you while patients face a private price tag. Taxpayers get acknowledged in the fine print; patients get handed the bill. If the public helps with the groundwork, it should not be treated like a stranger at the counter.

  • |

    The Internet Was Public Before It Was Billions

    ByLee Keybum

    I read the terms, and the tollbooth is already asking me to agree. Public research—from DARPA’s ARPANET to NSF-supported networking—helped lay the internet’s foundations. Now Google, Amazon, and Meta are among the private platforms doing business along that digital road. The contradiction isn’t that companies built nothing; it’s that shared groundwork can open the way to a digital economy where ordinary users still face private gates.

    We encounter the tolls as charges, exchanges of attention, or the price of convenience. The platform calls the gate innovation, then hands us a button marked “agree” and waits for our click like it just invented the road. We helped make the highway possible; now the tollbooth wants credit for the journey and our attention as the fare.

  • |

    The Public Helped Take AI’s Early Risk. It Deserves a Dividend.

    ByLee Keybum

    When public grants, labs, universities, or taxpayer-funded research help shoulder AI’s early risk, it’s odd to treat the upside as an investors-only boarding pass. I read the terms: innovation deserves a reward, but the public shouldn’t be the silent partner that helped build the runway and got left at the gate.

    An American dividend is a proposal, not an existing policy or settled funding plan. Still, if the public helped pay for takeoff, it deserves more than a thank-you and an in-flight safety card while private investors get the view from first class. Big Tech can call that innovation; ordinary people might ask who picked up the tab—and why they weren’t invited to share the return.

  • |

    The Internet’s Public Tab and Meta’s Private Receipt

    ByLee Keybum

    ARPANET, UCLA research, and DARPA belong in the internet’s origin story. Public and university work helped establish the foundations; Facebook arrived later as a private platform, and Meta built an advertising economy on top of the digital world people use. That isn’t the same as saying the public owned the whole internet or Meta took it over. It is a reason not to tell the platform’s success story as if every useful connection began with a company logo.

    Here’s my user-dividend audit: advertising and platform wealth on one side; ordinary people supplying attention, logging in, and accepting terms on the other. No legal claim to Meta’s profits is needed to ask why the rewards look so concentrated. The public helped lay some of the road. Our payout is access, a password reset, and another “agree” button. Somewhere, the tollbooth has a very good ad business.

  • |

    Google’s Public Starter Kit, Private Jackpot

    ByLee Keybum

    Lee Keybum here, reporting from the Terms of Surrender: Google grew inside a publicly supported scientific and technological ecosystem, then turned that runway into a private empire. That does not mean one company invented nothing. It means Big Tech loves treating public research, public infrastructure, and shared knowledge like a free starter kit while presenting concentrated wealth as the natural ending.

    Meanwhile, the ordinary user gets search results, targeted ads, another service agreement, and a privacy bargain written in font size suitable for ants. Google’s checkout screen should include a tip jar labeled “Taxpayer contribution.” The question is not whether private companies can build useful things. It is whether the public that helped make the conditions possible should receive more than the privilege of paying with attention, data, and an afternoon clicking “Agree.”

  • |

    NVIDIA Got the Chip, Taxpayers Got the Receipt

    ByPhil McCracken

    I opened the taxpayer invoice and found the usual public-private magic trick: grants, university science, and open research absorb the early risk, then NVIDIA turns the broader foundation into products while the public contribution vanishes from the paperwork. To be clear, that does not mean NVIDIA did nothing or that taxpayers legally own the company. It means the money trail deserves more than a ceremonial thank-you card.

    At the public invoice desk, the down payment is stamped complimentary, while the private payoff arrives with enough zeros to require its own zip code. Fair taxes, public reinvestment, or public-interest conditions are not radical demands when shared science helps make extraordinary fortunes possible. Follow the invoice and ask the plain question: if the public helped build the future, why is its return always listed as “pending”?

  • |

    Public Cancer Research, Private Cancer Profits: The Taxpayer Paid Twice

    ByPhil McCracken

    I followed the Taxol invoice, and the handwriting gets suspiciously fancy near the bottom. Publicly supported NIH research helped carry the scientific risk behind paclitaxel, while Bristol Myers Squibb became the name attached to the commercial blockbuster. The exact accounting deserves careful checking, but the central complaint is hard to miss: shared research can become private revenue before the public gets a meaningful return.

    That is the pharmaceutical business model in a lab coat. Taxpayers help finance the runway, private interests get the applause, and patients are handed the receipt for progress they helped make possible. Nobody objects to a company earning money by bringing a treatment to patients; the question is why public investment so often exits through the front door while public accountability is left waiting in the lobby. Follow the invoice long enough and “research for all” can end with profits for the private and a second bill for the sick.

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Your Phone Was Publicly Funded; Apple Sends the Rent

    ByLee Keybum

    Some of the smartphone’s essential toolkit grew from public research: networking, GPS, touch technology, and voice systems all benefited from government or university work. Then Apple arrived with excellent design, tight integration, and the confidence of a landlord who discovered marble. Suddenly the public foundation became invisible scenery behind a private miracle.

    Apple deserves credit for turning complicated tools into a product people actually want to use. But “we made it beautiful” is not the same as “we invented the whole toolbox.” Taxpayers helped raise the building; Apple added a luxury lobby, installed a platform toll booth, and started charging admission to the elevator. The museum gift shop now has a subscription barnacle, and somehow the receipt still says innovation.

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

End of content

End of content